HUP0203973A3 - Heterocyclic compounds having sulfonamide groups, pharmaceutical compositions containing them and their use - Google Patents
Heterocyclic compounds having sulfonamide groups, pharmaceutical compositions containing them and their useInfo
- Publication number
- HUP0203973A3 HUP0203973A3 HU0203973A HUP0203973A HUP0203973A3 HU P0203973 A3 HUP0203973 A3 HU P0203973A3 HU 0203973 A HU0203973 A HU 0203973A HU P0203973 A HUP0203973 A HU P0203973A HU P0203973 A3 HUP0203973 A3 HU P0203973A3
- Authority
- HU
- Hungary
- Prior art keywords
- pharmaceutical compositions
- compositions containing
- heterocyclic compounds
- sulfonamide groups
- sulfonamide
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000000565 sulfonamide group Chemical group 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP37548999 | 1999-12-28 | ||
PCT/JP2000/009326 WO2001047891A1 (fr) | 1999-12-28 | 2000-12-27 | Composes heterocylciques contenant des groupes de sulfamide |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0203973A2 HUP0203973A2 (hu) | 2003-03-28 |
HUP0203973A3 true HUP0203973A3 (en) | 2004-07-28 |
Family
ID=18505601
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0203973A HUP0203973A3 (en) | 1999-12-28 | 2000-12-27 | Heterocyclic compounds having sulfonamide groups, pharmaceutical compositions containing them and their use |
Country Status (16)
Country | Link |
---|---|
US (1) | US6787534B2 (hu) |
EP (1) | EP1243583B1 (hu) |
JP (1) | JP4234344B2 (hu) |
KR (1) | KR100641802B1 (hu) |
CN (1) | CN1217936C (hu) |
AT (1) | ATE305302T1 (hu) |
AU (1) | AU776933B2 (hu) |
CA (1) | CA2395772C (hu) |
DE (1) | DE60022906T2 (hu) |
ES (1) | ES2246922T3 (hu) |
HU (1) | HUP0203973A3 (hu) |
MX (1) | MXPA02006474A (hu) |
NO (1) | NO324268B1 (hu) |
NZ (1) | NZ519380A (hu) |
RU (1) | RU2239631C2 (hu) |
WO (1) | WO2001047891A1 (hu) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003074045A1 (fr) * | 2002-03-05 | 2003-09-12 | Eisai Co., Ltd. | Agent antitumoral comprenant une combinaison d'un compose heterocyclique contenant un sulfamide et d'un inhibiteur d'angiogenese |
US7030115B2 (en) | 2002-03-21 | 2006-04-18 | Abbott Laboratories | N-sulfonylurea apoptosis promoters |
ATE372330T1 (de) * | 2002-03-21 | 2007-09-15 | Abbott Lab | N-sulfonylurea-apoptosis-förderer |
EP1731507A1 (en) | 2005-04-26 | 2006-12-13 | Institut National des Sciences Appliquees de Rouen (INSA) | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents |
DK1893612T3 (da) | 2005-06-22 | 2011-11-21 | Plexxikon Inc | Pyrrol [2,3-B]pyridin-derivater som proteinkinasehæmmere |
WO2007008942A2 (en) * | 2005-07-11 | 2007-01-18 | Aerie Pharmaceuticals, Inc. | Phenylamino-acetic acid [1-(pyridin-4-yl)-methylidene]-hydrazide derivatives and related compounds as modulators of g protein-coupled receptor kinases for the treatment of eye diseases |
US7470787B2 (en) * | 2005-07-11 | 2008-12-30 | Aerie Pharmaceuticals, Inc. | Isoquinoline compounds |
KR101396783B1 (ko) * | 2005-10-07 | 2014-05-21 | 엑셀리시스, 인코포레이티드 | 포스파티딜이노시톨 3-키나아제 억제제 및 이의 사용 방법 |
AU2007214594B2 (en) * | 2006-02-13 | 2010-11-11 | F. Hoffmann-La Roche Ag | Heterobicyclic sulfonamide derivatives for the treatment of diabetes |
MX2009000919A (es) * | 2006-08-04 | 2009-04-16 | Merz Pharma Gmbh & Co Kgaa | Pirazolopirimidinas substituidas, proceso para su preparacion y su uso como medicina. |
ES2729424T3 (es) | 2006-09-20 | 2019-11-04 | Aerie Pharmaceuticals Inc | Inhibidores de Rho cinasa |
US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
TWI425945B (zh) * | 2007-05-28 | 2014-02-11 | Seldar Pharma Inc | 四氫異喹啉-1-酮衍生物或其鹽 |
US8455514B2 (en) | 2008-01-17 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-and 7-amino isoquinoline compounds and methods for making and using the same |
US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
ES2672624T3 (es) | 2009-05-01 | 2018-06-15 | Aerie Pharmaceuticals, Inc. | Inhibidores de mecanismo doble para el tratamiento de enfermedades |
US20220315555A1 (en) | 2009-05-26 | 2022-10-06 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
US9034875B2 (en) | 2009-05-26 | 2015-05-19 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
ME02205B (me) * | 2009-05-26 | 2016-02-20 | Abbvie Bahamas Ltd | INDUKUJUĆI AGENSI APOPTOZE ZA LEČENJE KANCERA I IMUNIH l AUTOIMUNIH OBOLJENJA |
US8329724B2 (en) | 2009-08-03 | 2012-12-11 | Hoffmann-La Roche Inc. | Process for the manufacture of pharmaceutically active compounds |
US20120196854A1 (en) | 2009-10-06 | 2012-08-02 | Kyowa Hakko Kirin Co., Ltd. | Pharmaceutical composition comprising aromatic heterocyclic compound |
KR20180059560A (ko) | 2010-10-29 | 2018-06-04 | 애브비 인코포레이티드 | 아폽토시스―유도제를 포함하는 고체 분산체 |
UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
AU2011332043C1 (en) | 2010-11-23 | 2016-11-10 | Abbvie Inc. | Salts and crystalline forms of an apoptosis-inducing agent |
UY33746A (es) | 2010-11-23 | 2012-06-29 | Abbott Lab | Método de tratamiento que usa inhibidores selectivos de bcl-2 |
CA2826892A1 (en) * | 2011-02-24 | 2012-08-30 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phosphorus containing compounds as protein kinase inhibitors |
US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
FI3811943T3 (fi) | 2013-03-15 | 2023-04-14 | Aerie Pharmaceuticals Inc | Yhdiste käytettäväksi silmäsairauksien hoidossa |
CN104447536B (zh) * | 2014-10-25 | 2017-04-12 | 大连理工大学 | 一种n‑2‑喹啉基芳基磺酰胺类化合物的制备方法 |
WO2016087593A1 (en) * | 2014-12-05 | 2016-06-09 | Syngenta Participations Ag | Novel fungicidal quinolinylamidines |
CN108601355B (zh) | 2015-11-17 | 2021-03-30 | 爱瑞制药公司 | 制备激酶抑制剂及其中间体的方法 |
US9643927B1 (en) | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
CN109640966A (zh) | 2016-08-31 | 2019-04-16 | 爱瑞制药公司 | 眼用组合物 |
CA3057872A1 (en) | 2017-03-31 | 2018-10-04 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
US11505544B2 (en) | 2017-12-15 | 2022-11-22 | Bayer Animal Health Gmbh | Process for preparing antihelmintic 4-amino-quinoline-3-carboxamide derivatives |
US11427563B2 (en) | 2018-09-14 | 2022-08-30 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
WO2020172615A1 (en) * | 2019-02-22 | 2020-08-27 | Glaukos Corporation | Compounds for the treatment of ocular disease |
WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
CA3188639A1 (en) | 2020-07-02 | 2022-01-06 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
WO2022046989A1 (en) | 2020-08-27 | 2022-03-03 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
WO2022140231A1 (en) | 2020-12-21 | 2022-06-30 | Incyte Corporation | Deazaguaine compounds as jak2 v617f inhibitors |
CA3211748A1 (en) | 2021-02-25 | 2022-09-01 | Incyte Corporation | Spirocyclic lactams as jak2 v617f inhibitors |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE9688C (de) | T. REMUS in Plauen bei Dresden | Filter | ||
DD9688A (hu) * | ||||
GB662798A (en) | 1948-05-06 | 1951-12-12 | American Cyanamid Co | Improvements in or relating to the production of sulphonamides and intermediates thereof |
NL76414C (hu) * | 1949-07-23 | |||
US3157684A (en) * | 1961-02-13 | 1964-11-17 | Atomic Energy Authority Uk | Tritiated-2-methyl-naphthaquinol-(1, 4)-diphosphoric acids |
US3801321A (en) | 1972-07-18 | 1974-04-02 | Eastman Kodak Co | Photothermographic element,composition and process |
GB1492029A (en) * | 1974-01-30 | 1977-11-16 | Bellon R Lab | 4-oxo-1,4-dihydro-1,6-benzo-(h)-naphthyridine-3-carboxylic acid derivatives useful as anti-bacterial agents and their preparation |
US4343804A (en) * | 1979-03-26 | 1982-08-10 | A. H. Robins Company, Inc. | 4-Amino-3-quinolinecarboxylic acids and esters-antisecretory anti-ulcer compounds |
US4333760A (en) * | 1980-08-22 | 1982-06-08 | E. I. Du Pont De Nemours And Company | Herbicidal sulfonamides |
JPS59220733A (ja) * | 1983-05-30 | 1984-12-12 | Konishiroku Photo Ind Co Ltd | ハロゲン化銀写真感光材料 |
DE3422824A1 (de) * | 1984-06-20 | 1986-01-02 | Celamerck Gmbh & Co Kg, 6507 Ingelheim | Neue herbizid wirksame sulfonylharnstoffe |
DE3686688T2 (de) | 1985-06-24 | 1993-03-18 | Merck & Co Inc | Verwendung von sulfanilamido quinoxalinen zur behandlung von neoplastischen krankheiten. |
WO1988003137A1 (en) * | 1986-10-28 | 1988-05-05 | Smith Kline & French Laboratories Limited | Tetrahydroisoquinolin-2-yl derivatives of carboxylic acids as thromboxane a2 antagonists |
US5089633A (en) * | 1987-04-28 | 1992-02-18 | Georgia Tech Research Corporation | Substituted isocoumarins |
DE3804990A1 (de) | 1988-02-18 | 1989-08-31 | Basf Ag | Herbizid wirksame, heterocyclisch substituierte sulfonamide |
JPH02149562A (ja) * | 1988-11-30 | 1990-06-08 | Nisshin Flour Milling Co Ltd | 相間移動触媒を用いた1,4−ジヒドロピリジン誘導体の製造方法 |
NZ233641A (en) | 1989-05-16 | 1992-07-28 | Merrell Dow Pharma | Quinoline and thienopyridine derivatives and excitatory amino acid antagonistic pharmaceutical compositions |
JPH03150560A (ja) * | 1989-11-08 | 1991-06-26 | Konica Corp | ハロゲン化銀カラー写真感光材料 |
DE4102234A1 (de) * | 1991-01-23 | 1992-07-30 | Dresden Arzneimittel | Neue (alpha)-aminochinolinoyl-(3)-penicilline, verfahren zu deren herstellung und diese enthaltende antibakterielle mittel |
JPH06199047A (ja) | 1993-01-08 | 1994-07-19 | New Oji Paper Co Ltd | 感熱記録体 |
JPH07138493A (ja) * | 1993-11-19 | 1995-05-30 | Konica Corp | 金属錯体化合物及び該化合物を用いた光記録媒体 |
US5529999A (en) | 1994-03-04 | 1996-06-25 | Eli Lilly And Company | Antitumor compositions and methods of treatment |
FR2725719B1 (fr) | 1994-10-14 | 1996-12-06 | Jouveinal Inst Rech | Diazepino-indoles inhibiteurs de phosphodiesterases iv |
CN1201393A (zh) * | 1995-10-23 | 1998-12-09 | 酶遗传学股份有限公司 | 治疗骨缺陷疾病的组合物及方法 |
DE19727117A1 (de) | 1997-06-26 | 1999-01-07 | Boehringer Ingelheim Pharma | Phenylalkylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
TW527355B (en) * | 1997-07-02 | 2003-04-11 | Bristol Myers Squibb Co | Inhibitors of farnesyl protein transferase |
DE60141889D1 (de) * | 2000-02-03 | 2010-06-02 | Eisai R&D Man Co Ltd | Inhibitoren der integrinexpression |
-
2000
- 2000-12-27 JP JP2001549363A patent/JP4234344B2/ja not_active Expired - Fee Related
- 2000-12-27 CA CA2395772A patent/CA2395772C/en not_active Expired - Fee Related
- 2000-12-27 CN CN008180059A patent/CN1217936C/zh not_active Expired - Fee Related
- 2000-12-27 AT AT00985953T patent/ATE305302T1/de not_active IP Right Cessation
- 2000-12-27 ES ES00985953T patent/ES2246922T3/es not_active Expired - Lifetime
- 2000-12-27 RU RU2002120515/04A patent/RU2239631C2/ru not_active IP Right Cessation
- 2000-12-27 US US10/149,253 patent/US6787534B2/en not_active Expired - Fee Related
- 2000-12-27 HU HU0203973A patent/HUP0203973A3/hu unknown
- 2000-12-27 DE DE60022906T patent/DE60022906T2/de not_active Expired - Lifetime
- 2000-12-27 EP EP00985953A patent/EP1243583B1/en not_active Expired - Lifetime
- 2000-12-27 NZ NZ519380A patent/NZ519380A/en not_active IP Right Cessation
- 2000-12-27 AU AU22283/01A patent/AU776933B2/en not_active Ceased
- 2000-12-27 MX MXPA02006474A patent/MXPA02006474A/es active IP Right Grant
- 2000-12-27 WO PCT/JP2000/009326 patent/WO2001047891A1/ja active IP Right Grant
- 2000-12-27 KR KR1020027008281A patent/KR100641802B1/ko not_active IP Right Cessation
-
2002
- 2002-06-26 NO NO20023097A patent/NO324268B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
NO324268B1 (no) | 2007-09-17 |
ES2246922T3 (es) | 2006-03-01 |
NO20023097D0 (no) | 2002-06-26 |
CN1217936C (zh) | 2005-09-07 |
DE60022906D1 (de) | 2006-02-09 |
MXPA02006474A (es) | 2002-11-29 |
HUP0203973A2 (hu) | 2003-03-28 |
US6787534B2 (en) | 2004-09-07 |
AU776933B2 (en) | 2004-09-23 |
JP4234344B2 (ja) | 2009-03-04 |
US20030144507A1 (en) | 2003-07-31 |
WO2001047891A1 (fr) | 2001-07-05 |
KR100641802B1 (ko) | 2006-11-02 |
EP1243583B1 (en) | 2005-09-28 |
RU2002120515A (ru) | 2004-01-10 |
RU2239631C2 (ru) | 2004-11-10 |
CA2395772A1 (en) | 2001-07-05 |
KR20020068388A (ko) | 2002-08-27 |
CA2395772C (en) | 2010-09-28 |
CN1414952A (zh) | 2003-04-30 |
NO20023097L (no) | 2002-08-28 |
NZ519380A (en) | 2004-10-29 |
EP1243583A1 (en) | 2002-09-25 |
DE60022906T2 (de) | 2006-07-06 |
AU2228301A (en) | 2001-07-09 |
EP1243583A4 (en) | 2003-08-20 |
ATE305302T1 (de) | 2005-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0203973A3 (en) | Heterocyclic compounds having sulfonamide groups, pharmaceutical compositions containing them and their use | |
HUP0200714A3 (en) | Pharmaceutical compounds, pharmaceutical compositions containing them and their use | |
HUP0302969A3 (en) | Npyy5 antagonists, pharmaceutical compositions containing them and their use | |
IL202633A0 (en) | Sulfonamide derivatives and pharmaceutical compositions containing the same | |
IL148517A0 (en) | Heterocyclic compounds and pharmaceutical compositions containing the same | |
IL150077A0 (en) | Heterocyclic compounds and pharmaceutical compositions containing the same | |
HUP0204081A3 (en) | 4-pyrimidinyl-n-acyl-l-phenylalanines, pharmaceutical compositions containing them and their use | |
HUP0203939A3 (en) | Pharmaceutical compounds and compositions containing them and their use | |
HUP0400540A3 (en) | 2-pyrazolin-5-one derivatives, their use and pharmaceutical compositions containing them | |
HUP0203403A3 (en) | New imidazole derivatives, pharmaceutical compositions containing them and their use | |
HUP0200308A2 (en) | Quinolinecarboxamides as antiviral agents, pharmaceutical compositions containing them and their use | |
IL148876A0 (en) | Sulfonamide derivatives, their preparation and pharmaceutical compositions containing them | |
HUP0200355A3 (en) | 4-aminopyrrolopyrimidines as kinase inhibitors, pharmaceutical compositions containing them and their use | |
HUP0401567A3 (en) | Novel 4,5-dyhydro-1h-pyrazole derivatives having cb1-antagonistic activity, their use and pharmaceutical compositions containing them | |
HUP0400058A2 (hu) | Kondenzált heterogyűrűs vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
HUP0400837A3 (en) | 2-phenyl-thiazole derivatives, their use and pharmaceutical compositions containing them | |
IL144592A0 (en) | Heterocyclic aromatic compounds and pharmaceutical compositions containing the same | |
HUP0204474A3 (en) | 1h-imidazopyridine derivatives, pharmaceutical compositions containing them and their use | |
HUP0400467A3 (en) | 2-iminopyrrolidine derivatives, pharmaceutical compositions containing them and their use | |
HUP0301573A3 (en) | Substituted arylpyrazines, pharmaceutical compositions containing them and their use | |
HUP0103884A3 (en) | Arylsulfonanilide urea-derivatives, pharmaceutical compositions containing them and their use | |
HUP0203194A3 (en) | Phenylpiperazines, pharmaceutical compositions containing them and their use | |
HUP0203735A3 (en) | 4-pyridinyl-n-acyl-l-phenylalanines, pharmaceutical compositions containing them and their use | |
HUP0200996A3 (en) | Amine derivatives, pharmaceutical compositions containing them and their use | |
HUP0101333A3 (en) | Diazepan derivatives and their salts, pharmaceutical compositions containing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB9A | Succession in title |
Owner name: EISAI R&D MANAGEMENT CO., LTD., JP Free format text: FORMER OWNER(S): EISAI CO., LTD., JP |
|
FD9A | Lapse of provisional protection due to non-payment of fees |